DXB have a current MC of about $170M. Not much for a phase 3. They shoud be double that but they did a CR at recent interim analysis, leveling their price to 30c.
We are very similar to DXB.... however.... PER should beat them to market off the strength of our Ph2B results. DXB may gain market approval early in places like China after their next interim analysis mid next year. However PER could gain market approval mid next year also. DXB have performance over placebo, PER undoubtably have performance well beyond placebo into stabalisation above baseline... which is why I'm here.
So in a race to sellling drugs PER are ahead IMO, and yet DXB are more than double our MC, and should be tripple it's just they're having a mexican standoff with potential partners using their recent CR to move forward with.
PER Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
